CARDIOVASCULAR RESPONSES TO CEREBRAL ISCHEMIA FOLLOWING BILATERAL CAROTID ARTERY OCCLUSION IN SHRSP, SHRSR AND WKY RATS

Mitsuru KAKIHANA, Akio SHINO and Akinobu NAGAOKA
Biology Laboratories, Central Research Division, Takeda Chemical Industries Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532, Japan

Accepted July 31, 1982

Abstract—Systemic arterial pressure was markedly increased in the early phase of cerebral ischemia induced by bilateral carotid artery occlusion (BCAO) in stroke-prone spontaneously hypertensive rats (SHRSP). The elevated level of arterial pressure was gradually returned to the initial level, and hypotension followed in the late phase. Severe neurological symptoms such as "ischemic seizure", dyspnea and coma were developed in the late phase. All SHRSP died within 6 hr after BCAO. The heart rate continued to increase during the brain ischemia. Cardiac arrhythmias, significant increases in plasma levels of creatine phosphokinase (CPK) and CPK-MB isozyme and disruption of myofibrils were observed after BCAO, particularly after the development of ischemic seizure. In contrast, in stroke-resistant SHR (SHRSR) and Wistar-Kyoto rats (WKY), ischemic seizure did not develop, yet all died within 8 hr after BCAO. Arterial pressures were moderately increased and never decreased to below the initial levels during the observation periods. Increases in CPK-MB isozyme activities in plasma from SHRSR and WKY were not detected. Pretreatments with propranolol and reserpine inhibited the increases in heart rate, reduced the frequency of arrhythmias and prolonged the survival time following BCAO in SHRSP. Our results indicate that cardiac dysfunction, which is a consequence of the cerebral ischemia, may be one of the causes of death following BCAO in SHRSP.

Bilateral carotid artery occlusion (BCAO) causes a marked brain ischemia in spontaneously hypertensive rats (SHR) and a stroke-prone strain of SHR (SHRSP) (1-4). In both these strains of SHR, after BCAO, cerebral anaerobic metabolites were increased and adenosine triphosphate were decreased, leading to the development of various neurological symptoms. Clinical studies (5-11) in patients with acute cerebrovascular accidents demonstrated a high incidence of cardiac arrhythmias and other electrocardiographic (ECG) abnormalities, histological changes in the myocardium, and elevated levels of serum cardiac enzymes such as creatine phosphokinase (CPK) and lactate dehydrogenase (LDH). Dimant and Grob (10) reported that twenty-nine percent of the patients with stroke had raised serum enzyme levels, and those with elevated CPK levels had a higher incidence of ECG abnormality as well as a higher mortality than those with normal CPK levels.

In the present study, we attempted to elucidate the relationship between the alteration of the cardiovascular system and the development of neurological deficits following BCAO in the SHRs and control Wistar-Kyoto rats (WKY). We examined the changes in systemic arterial pressure, heart rate, ECG, plasma levels of cardiac enzymes and isozyme patterns, histological changes in the myo-
cardium, and ischemic neurological deficits in conscious rats. Effects of antiadrenergic drugs on these so-induced changes were evaluated.

Materials and Methods

General: Male stroke-prone spontaneously hypertensive rats (SHRSP), a stroke-resistant SHR (SHRSR) and normotensive Wistar-Kyoto rats (WKY), 10–11 weeks of age, were used. The rats had been raised in our laboratories and given a laboratory chow, CE-2, Japan Clea and tap water ad libitum. Under light ether anesthesia, the bilateral common carotid arteries were exposed through a ventral midline incision in the neck and were separated carefully from vagosympathetic trunks. When the rats had recovered from ether anesthesia after 5 min, the arteries were simultaneously ligated with silk sutures, and the skin incision was closed with steel clips. Neurological symptoms after BCAO were scored as follows: 0, normal; 1, slight decrease in spontaneous motor activity; 2, no ambulation and weakness of hindlimb; 3, weakness of all four limbs, and presence of righting reflex; 4, weakness of all limbs, and no lighting reflex; 5, piloerection and tremor; 6, jumping and/or seizure (ischemic seizure); 7, dyspnea or coma; 8, death.

Hemodynamics and neurological changes: Systemic arterial pressure, heart rate and ischemic neurological symptoms following BCAO were examined in SHRSP (N=8), SHRSR (N=6) and WKY (N=6). The femoral artery was cannulated with a polyethylene tube (PE-10) filled with sodium heparin (100 IU/ml in 0.9% NaCl). This tube was reflected dorsally and anteriorly, led subcutaneously to the back of the neck, and exteriorized through a small skin puncture. The catheter was flushed occasionally with saline containing 100 IU sodium heparin per ml to prevent blood clotting. The rats were placed individually in a transparent plastic cylinder (22 cm diam., 55 cm height). Mean arterial pressure was measured via a femoral arterial catheter with a pressure transducer (MPU-0.5) and polygraph (RM-45, Nihon Koden, Tokyo). Heart rate was calculated from the blood pressure tracing. Thirty minutes after surgery, mean arterial pressure and heart rate were recorded as the initial values. The changes in blood pressure and heart rate and the development of neurological symptoms were observed for 8 hr and at 24 hr after BCAO. Because jumping and/or seizure was the most unequivocal symptom (termed ischemic seizure), the time which elapsed until onset of the ischemic seizure and death were recorded. In rats with no ischemic seizure up to 8 hr, the time was recorded as 480 min.

Plasma enzymes: Changes in plasma lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) contents and their isozyme patterns after BCAO were determined in SHRSP (N=20), SHRSR (N=15) and WKY (N=15). Sham-operated rats were used as controls. Under ether anesthesia, the blood of each rat was sampled from the abdominal aorta. The plasma was stored at −20°C until assayed. CPK and LDH contents were estimated with the activated ultraviolet test set of Boehringer (Mannheim) and the LDH test set of Wako (Osaka), respectively. CPK and LDH isozymes were fractionated by agarose electrophoresis (CPK isozymes, Sigma 715-PE, St. Louis) and agar electrophoresis (LDH isozyme-test, Wako, Osaka), respectively. Both CPK and LDH isozymes were visualized by formation of formazan. Quantitation of CPK-isozymes was accomplished by colorimetric scanning using a densitometer (TLC scanner, Shimadzu CS-910, Kyoto).

Electrocardiogram: Changes in electrocardiogram (ECG) following BCAO were recorded in five conscious SHRSP since only
SHRSP showed a marked change in arterial pressure in the preliminary experiments. Limb leads were constructed from small needle electrodes placed subcutaneously at the fore-limbs and the left hind-limb, and the electrodes were fixed with adhesive tape. The femoral artery was cannulated as described above. Systemic arterial pressure and ECG (lead II) were recorded simultaneously on a polygraph.

Effects of antiadrenergic drugs: Effects of antiadrenergic drugs on the development of cardiovascular and neurological abnormalities were observed in SHRSP. Twenty-four rats were assigned to four groups. DL-propranolol hydrochloride at 2 mg/kg, phentolamine mesylate at 5 mg/kg or saline at 2.5 ml/kg was subcutaneously administered 30 min before BCAO. Reserpine at 2 mg/kg and 1 mg/kg was subcutaneously administered about 16 hr and 30 min before BCAO, respectively. Mean arterial pressure and heart rate were recorded via a femoral arterial catheter implanted 1 hr before BCAO. The transient, precipitous fall in blood pressure was regarded as a sign of ventricular arrhythmias occurring between BCAO and the development of ischemic seizure, and the severity of arrhythmias was represented as a frequency per 10 min. Changes in neurological symptoms and ECG were observed for 8 hr after BCAO. In rats with no ischemic seizure up to 8 hr, the onset-time of ischemic seizure was recorded as 480 min.

Histological examination: Histological examination was carried out with the hearts from SHRSP which were sacrificed at 0, 30, 90 and 180 min after BCAO. The hearts were fixed with buffered 10% formalin and embedded in paraffin. Sections of 5 μ thickness were cut and stained with hematoxylin and eosin.

Statistical analysis: Statistical differences were evaluated using the Mann-Whitney U-test for plasma enzyme levels and for the time required for the onset of ischemic seizure and death following BCAO, and the Student's t-test was used for the others. All values were expressed as the mean±S.E.M.

Results

Hemodynamics and neurological changes: Mean arterial pressures before BCAO were 166±5, 126±4 and 107±2 mmHg in SHRSP, SHRSR and WKY, respectively (Table 1). Heart rates were similar in the three strains. In SHRSP, there were observed a decrease in spontaneous motor activity and a marked weakness of all the limbs (score 1-3) within 60 min after BCAO. The time required for onset of ischemic seizure (score 6) was 112±10 min (Table 1). Thereafter, the animals became dyspneic or comatose (score 7) and died within 6 hr after BCAO, with an average death time of 248±16 min. In contrast, in SHRSR and WKY, ischemic seizure did not develop, yet all died within 8 hr after BCAO. Some of SHRSR and WKY showed only slight neurological abnormalities (score 1-3).

Table 1. Initial mean arterial pressure (MAP), heart rate (HR) and time required for onset of ischemic seizure and survival time following bilateral carotid artery occlusion (BCAO) in WKY, SHRSR and SHRSP

<table>
<thead>
<tr>
<th></th>
<th>WKY</th>
<th>SHRSR</th>
<th>SHRSP</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP (mmHg)</td>
<td>107±2</td>
<td>126±4*</td>
<td>166±5*</td>
</tr>
<tr>
<td>HR (beats/min)</td>
<td>384±18</td>
<td>361±13</td>
<td>367±10</td>
</tr>
<tr>
<td>Onset time of ischemic seizure (min)</td>
<td>&gt;480</td>
<td>&gt;480</td>
<td>112±10*</td>
</tr>
<tr>
<td>Survival time (min)</td>
<td>&gt;480</td>
<td>&gt;480</td>
<td>248±16*</td>
</tr>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
<td>8</td>
</tr>
</tbody>
</table>

\*P<0.001 vs WKY, \*P<0.001 vs SHRSR. Values are the mean±S.E.M.
Fig. 1. Changes in mean arterial pressure (MAP) and heart rate (HR) following BCAO in SHRSP.
MAP, C—••—••, HR, •—•—•. Each point is the mean±S.E.M. of 8 rats. Time-course of MAP and HR changes are constructed from three periods: left, the first 1-hr period following BCAO; center, the 30-min period before and after the first development of ischemic seizure; right, the 1-hr period before death following BCAO. MAP and HR were determined every 10 min in each period.

Time-course of arterial pressure changes following BCAO in SHRSP is shown in Fig. 1, and a representative recording is given in Fig. 2. In the early phase of cerebral ischemia, mean arterial pressure rose markedly immediately after BCAO, and reached a level of 222±3 mmHg 10 min later. The elevated level lasted for about 30 min and then returned to the initial level within 90 min. In the late phase of cerebral ischemia, transient but marked elevation of blood pressure was observed at the time when the ischemic seizure developed. The average increment was about 100 mmHg at the first development of the seizure (Fig. 1). After the repeated occurrence of ischemic seizure, arterial pressure was further decreased to hypotensive levels. Heart rate continued to increase during the brain ischemia (Fig. 1). Arterial pressure and heart rate in SHRSR and WKY were moderately increased and never decreased to below the initial levels. In SHRSR, mean arterial pressure gradually increased to 175–180 mmHg at 40–80 min after BCAO and returned to the initial level within 8 hr. In WKY, the arterial pressure slightly increased to a level of about 130 mmHg at 20 min after BCAO. The elevated level continued during the observation period. Heart rate in these strains of rats slightly increased, but returned to the initial level within 3 hr.

Plasma enzyme activities: Alterations in plasma LDH and CPK activities and LDH and CPK isozyme patterns after BCAO in SHRSP, SHRSR and WKY are shown in Table 2 and Figs. 3 and 4. In SHRSP, both total LDH and CPK levels were significantly increased after BCAO. Increases in the levels were much more pronounced at 3 than 1 hr after BCAO. LDH1 and LDH2 isozymes not detectable in the plasma of sham-operated controls, were identified (Fig. 3). Moreover, a marked increase in CPK-MB isozyme was observed in SHRSP, particularly in the SHRSP with severe neurological deficits (score 7) and hypotension (Figs. 4 and 5).

Total LDH and CPK levels in WKY and SHRSR were increased slightly but significantly. Increases in cardiac enzymes such as LDH1 and LDH2 isozymes or CPK-MB isozyme in plasma from SHRSR and WKY were nil (Figs. 3 and 4).

Electrocardiogram: A transient but marked fall in blood pressure (Fig. 2, at 50 min of BCAO) sometimes followed BCAO in the SHRSP. When the transient and precipitous
fall of blood pressure (Fig. 6, left) and seizures (Fig. 6, right) occurred, cardiac rhythm disturbances such as single and multiple ventricular premature beats were observed. These arrhythmias were noted in every SHRSP so-tested.

Table 2. Changes in plasma lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) activities following BCAO in WKY, SHRSR and SHRSP

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Time (hr) after BCAO</th>
<th>WKY</th>
<th>SHRSR</th>
<th>SHRSP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDH</td>
<td>1</td>
<td>180±28 (N=5)</td>
<td>161±11 (N=5)</td>
<td>166±10 (N=5)</td>
</tr>
<tr>
<td>(U/ml)</td>
<td>3</td>
<td>162±15 (N=4)</td>
<td>189±16 (N=5)</td>
<td>688±86 (N=9)***</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPK</td>
<td>1</td>
<td>31±8 (N=5)</td>
<td>41±3 (N=5)*</td>
<td>57±11 (N=5)**</td>
</tr>
<tr>
<td>(U/l)</td>
<td>3</td>
<td>59±4 (N=4)*</td>
<td>37±1 (N=5)*</td>
<td>264±50 (N=9)***</td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01, ***P<0.001 vs the control. ( )=number of rats. Values are the mean±S.E.M.

In an attempt at elucidating the effect of antiadrenergic drugs on the occurrence of cardiac arrhythmias in SHRSP, the frequency of the transient and precipitous fall of blood pressure between BCAO and development of ischemic seizure was determined to assess the severity of the cardiac arrhythmias.

Effects of antiadrenergic drugs: Effects of antiadrenergic drugs on mean arterial pressure, heart rate, frequency of arrhythmias and onset-times of ischemic seizure and death following BCAO in SHRSP are summarized in Table 3. Propranolol and reserpine decreased the heart rate, reduced the frequency of arrhythmias and prolonged the survival time. In addition, reserpine decreased the pressor response and prolonged the onset-time of ischemic seizure. On the other hand, phentolamine inhibited the pressor response, but not the frequency of cardiac arrhythmias: As a result, the onset-time of ischemic seizure was accelerated, and the elapse of time to death was tended to be shortened.

Histological findings in the heart: The hearts of SHRSP showed spontaneous, slight lesions such as cytoplasmic micro-

Fig. 3. Plasma lactate dehydrogenase isozyme patterns 1 and 3 hr after BCAO in WKY (A), SHRSR (B) and SHRSP (C). The origin is indicated by the arrow. Neurological symptoms: score 0, normal; score 1, slight decrease in spontaneous motor activity; score 5, piloerection and tremor; score 7, dyspnea or coma.

Fig. 4. Plasma creatine phosphokinase isozyme patterns 1 and 3 hr after BCAO in WKY (A), SHRSR (B) and SHRSP (C). The origin is indicated by the arrow. Neurological symptoms: score 0, normal; score 1, slight decrease in spontaneous motor activity; score 5, piloerection and tremor; score 7, dyspnea or coma.
vacuolation, focal or single cell necrosis and focal fibrosis (Table 4). At 30 min after BCAO, a slight increase in cytoplasmic vacuoles was observed in one out of three SHRSP. In the late phase of BCAO, degeneration of cardiocytes which showed focal disruption or loss of myofibrils was detected. The myofibrilar degeneration was more prominent in the SHRSP sacrificed at 180 min (Fig. 7, Table 4).

Discussion

The pathogenetic mechanism of cerebral ischemia after BCAO in SHR has been studied by Fujishima et al. (1–3, 12, 13). They found that the increased vascular resistance due to persistent high blood pressure in SHR might be responsible for an upward shift of cerebral blood flow auto-

Fig. 5. Relationship between neurological symptoms and plasma CPK-MB isozyme activity following BCAO in SHRSP. Neurological symptoms: score 0, normal; score 3, weakness of all limbs; score 5, piloerection and tremor; score 7, dyspnea or coma. The difference of CPK-MB activity between score 0 and score 7 is statistically significant (P<0.001). ○, control; ●, 1 hr after BCAO; △, 3 hr after BCAO.

Fig. 6. Representative recording of cardiac arrhythmias following BCAO in SHRSP.

Fig. 7. Cardiocyte of SHRSP sacrificed 180 min after BCAO. Many cardiocytes show disruption or loss of myofibrils in both transverse and longitudinal sections. H.E. stain. Left: transverse section, ×260. Right: longitudinal section, ×520.
Table 3. Effects of antiadrenergic drugs on mean arterial pressure, heart rate, cardiac arrhythmias, time required for onset of ischemic seizure and survival time following BCAO in SHRSP

<table>
<thead>
<tr>
<th></th>
<th>Saline</th>
<th>Propranolol</th>
<th>Reserpine</th>
<th>Phentolamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5 ml/kg</td>
<td>2 mg/kg</td>
<td>2 mg/kg</td>
<td>2 mg/kg +1 mg/kg</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>MAP† (mmHg) initial</td>
<td>154±4</td>
<td>147±5</td>
<td>105±1***</td>
<td>151±4</td>
</tr>
<tr>
<td>30 min after BCAO</td>
<td>235±4</td>
<td>226±3</td>
<td>164±6***</td>
<td>140±13***</td>
</tr>
<tr>
<td>HR† (beats/min) initial</td>
<td>351±11</td>
<td>355±7</td>
<td>235±6***</td>
<td>340±4</td>
</tr>
<tr>
<td>30 min after BCAO</td>
<td>402±15</td>
<td>257±9***</td>
<td>222±8***</td>
<td>414±13</td>
</tr>
<tr>
<td>Cardiac arrhythmias†† (frequency per 10 min)</td>
<td>3.0±0.8</td>
<td>1.2±0.4‡</td>
<td>1.1±0.2*</td>
<td>3.1±0.9</td>
</tr>
<tr>
<td>Onset time of ischemic seizure (min)</td>
<td>107±12</td>
<td>110±16</td>
<td>387±67*</td>
<td>78±12*</td>
</tr>
<tr>
<td>Survival time (min)</td>
<td>277±44</td>
<td>449±31**</td>
<td>&gt;480***</td>
<td>180±47</td>
</tr>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

†P<0.1, *P<0.05, **P<0.01, ***P<0.001 vs saline. Values are the mean±S.E.M. †: MAP and HR were measured 30 min before and after BCAO. ††: The number of transient decreases in blood pressure between BCAO and development of ischemic seizure was used to evaluate the cardiac arrhythmias and were represented as a frequency per 10 min. All drugs except reserpine were given s.c. 30 min before BCAO. Reserpine at 2 mg/kg and 1 mg/kg were given s.c. 16 hr and 30 min before BCAO, respectively.

Table 4. Histological findings with the heart of SHRSP after BCAO

<table>
<thead>
<tr>
<th>Animal No.</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal necrosis of myocytes</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Focal fibrosis</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Microvacuolation of myocytes</td>
<td>4</td>
<td>4</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Disruption of myofibrils</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Score of neurological symptoms</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

Severity of lesion: +, weak; ++, moderate; ++++, severe. Neurological symptoms: score 0, normal; score 3, weakness of all limbs; score 5, piloerection and tremor; score 6, ischemic seizure; score 7, dyspnea or coma.
regulation and a marked reduction of the cerebral perfusion pressure after BCAO, resulting in severe brain ischemia. The stroke-prone strain of SHR (SHRSP) shows a steeper rise of blood pressure at an early stage of hypertension (14). It has been also found that the distribution of cerebral arteries is essentially the same between SHR and WKY (15) and between SHRSP and WKY (16). These findings indicate that a functional mechanism in cerebral circulation rather than a morphological one may account for the increased sensitivity to brain ischemia in the SHRs. In a previous study (17), in which neurological symptoms and cerebral metabolic changes after BCAO were observed in SHRSP, SHRSR, WKY and thier F1 and F2 hybrids, we showed that not only hypertension but also genetic factors may play an important role in the susceptibility to brain ischemia in SHRSP.

It is well known that the primary and acute response to brain ischemia consists of arterial hypertension, bradycardia and apnea (18-22). The rise in arterial pressure is due to an increased peripheral vasoconstriction which is primarily neurogenic and mediated by a-adrenergic receptors. Recently, Dampney et al. (23) reported that the pressor response to cerebral ischemia, caused by clamping both common carotid arteries after previously occluding the vertebral arteries of anesthetized rabbits, was mediated by a restricted region in the medulla oblongata. In the present experiment, characteristic responses in the cardiovascular system to BCAO were evident in stroke-prone SHR. Systemic arterial pressure was markedly elevated in the early phase of brain ischemia. The pressor response was inhibited by an a-blocker, phentolamine, but not a b-blocker, propranolol. Bradycardia and apnea, however, could not be observed in the early phase of brain ischemia in SHRSP. This difference in cardiovascular response to cerebral ischemia seems to be due to the difference in the type of cerebral ischemia. In the previous studies, most experiments were performed under the condition of almost complete ischemia. In SHRSP with BCAO, the regional blood flow in the cerebral cortex was decreased to about 20% of the basal value and that in the brainstem including the medulla oblongata did not change in the early phase of cerebral ischemia (4). Further work will be needed to elucidate the detailed neural mechanism involved in the cardiovascular responses to cerebral ischemia following BCAO in SHRSP.

Knowledge of the level of serum cardiac enzymes (LDH, CPK etc.) is pertinent to evaluate the extent of cardiac damage. Of these enzymes, the serum levels of CPK and CPK-MB isozyme proved to be the most useful indicators of myocardial damage (24, 25). A growing body of clinical and experimental data revealed that cerebrovascular lesions exhibit a high incidence of ECG abnormalities and arrhythmias with elevated serum levels of cardiac enzymes (11, 12, 26, 27). Plasma levels of LDH and CPK were markedly increased after BCAO in SHRSP. The degree of increases in CPK-MB tended to be correlate with severity of the neurological symptoms. In addition, cardiac arrhythmias was detected during the period of brain ischemia, particularly in the late phase. These findings strongly suggest that brain ischemia induces myocardial dysfunction in SHRSP. In fact, disruption of myofibrils was found in the late phase of cerebral ischemia in SHRSP.

The marked elevation of systemic arterial pressure in SHRSP with BCAO was followed by gradual return to the initial level in the early phase of brain ischemia. After repeated occurrence of ischemic seizure, arterial pressure was further decreased to a hypotensive level in the late phase. It should be stressed that cardiac rhythm disturbances and release of CPK-MB isozyme from the myocardium
were detected in the early phase of brain ischemia. Moreover, focal myocardial necrosis and fibrosis were observed in SHRSP with and without BCAO. Yamori et al. (28) have already reported that genetic hypertension accompanied by left ventricular hypertrophy with thickening of coronary arterial wall may be a pathogenetic factor for myocardial lesions or myocardial infarction in SHRSP. These pathophysiological changes in the heart of SHRSP may explain the increased susceptibility to myocardial damage due to cerebral ischemia, leading to the development of arrhythmias, the release of cardiac enzymes, and the breakdown of pressor response (compensatory response) in the SHRSP.

It has been reported (28–30) that hearts subjected to coronary artery occlusion are hyperreactive to arrhythmogenic effects of catecholamines and that reserpine and propranolol prevent the occurrence of cardiac arrhythmias in such hearts. These drugs also limited the enzyme release from the myocardium in the experimental ischemic and hypoxic hearts (31–34). In addition, in clinical and experimental studies (35–39), propranolol and reserpine ameliorated the ECG changes and myocardial lesions occurring in cerebrovascular accidents. In the present study, pretreatment with reserpine and propranolol reduced the frequency of cardiac arrhythmias and prolonged the survival time after BCAO in SHRSP. All these findings suggest that the disturbance of cardiac function may be one of the causes of death after BCAO in SHRSP.

Acknowledgment: We thank M. Ohara of Kyushu University and Dr. K. Kikuchi for comments on the manuscript.

References
Physiol. 230, 1354-1359 (1976)


